Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient

Fadi Farhat 1Mohammad Tarabaih 1Ali Kanj 2Majeda Aoun 2Joseph Kattan 3Tarek Assi 1 4Ahmad Awada 5


1Oncology Department, Hammoud Hospital UMC.

2Radiology Department, Hammoud Hospital UMC, Saida.

3Oncology Department, Hotel-Dieu de France, Faculty of Medicine, Saint-Joseph University.

4Oncology Department, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.

5Oncology Medicine Department, Jules Bordet Institute, Université Libre de Bruxelles, Bruxelles, Belgium.

PMID: 31609762

DOI: 10.1097/CAD.0000000000000845


CDK4/6 inhibitors in association with aromatase inhibitors have led to a paradigm shift in the management of metastatic positive hormone-receptors breast cancer. Liver toxicity is common with these agents, but no data are reported on the sequential use of these CDK4/6 inhibitors in case of confirmed efficacy and intolerable toxicity. In this article, we report the successful use of Palbociclib in a metastatic positive hormone-receptors breast cancer patient after initial response to Ribociclib, which was interrupted for grade 4 liver toxicity.